MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Coherus BioSciences Net Income 2011-2026 | CHRS
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Coherus BioSciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -238 M | -292 M | -287 M | 132 M | 89.8 M | -209 M | -238 M | -127 M | -223 M | -87.1 M | -53.6 M | -33 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | -292 M | -131 M |
Quarterly Net Income Coherus BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.5 M | 298 M | -56.6 M | - | -10.8 M | -12.9 M | 103 M | - | -39.6 M | -42.9 M | -75.7 M | - | -86.6 M | -50.2 M | -96.1 M | - | -38.5 M | -29.9 M | -173 M | - | 27.9 M | 59 M | 35.6 M | 39.2 M | 47 M | 23.6 M | -20 M | -62.6 M | -58.8 M | -43.6 M | -44.3 M | -49.1 M | -59 M | -55.3 M | -74.8 M | -75.9 M | 83.9 M | -70 M | -65.4 M | -52.4 M | -71.3 M | -58.8 M | -40.7 M | -29.1 M | -7.87 M | -25 M | -25.2 M | -14.6 M | -21.5 M | -8.71 M | -8.86 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 298 M | -173 M | -23.4 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-208 M | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
-33.4 M | $ 1.65 | 7.91 % | $ 92.9 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 3.59 | 1.99 % | $ 8.64 B |  Australia |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 M | $ 66.05 | 2.3 % | $ 8.83 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-221 M | $ 1.52 | -16.3 % | $ 388 M |  Britain |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Biogen
BIIB
|
1.63 B | $ 184.48 | -1.67 % | $ 26.9 B | USA |
 |
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
BioNTech SE
BNTX
|
10.3 B | $ 102.17 | 2.32 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AstraZeneca PLC
AZN
|
115 M | $ 93.52 | -1.2 % | $ 96.9 B | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.88 M | $ 4.25 | 1.67 % | $ 9.25 B |  Israel |
 |
BeiGene, Ltd.
BGNE
|
-645 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
-25 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-98 M | - | -7.31 % | $ 87 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
-8.95 B | $ 55.71 | -0.28 % | $ 113 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 207.49 | 2.22 % | $ 5 B |  Danmark |
 |
Codiak BioSciences
CDAK
|
-37.2 M | - | -55.98 % | $ 2.15 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
-433 M | - | - | $ 7.29 B | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M |  Canada |
 |
Zai Lab Limited
ZLAB
|
-257 M | $ 18.37 | -0.97 % | $ 18.2 B | China |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 10.84 | 0.46 % | $ 714 M | USA |
 |
Caladrius Biosciences
CLBS
|
-20 M | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
-158 M | $ 25.59 | -6.54 % | $ 1.65 M | USA |
 |
Cellectis S.A.
CLLS
|
-125 M | $ 4.22 | -4.2 % | $ 116 M | France |
 |
Clearside Biomedical
CLSD
|
-32.5 M | - | - | $ 25.3 M | USA |
 |
Chimerix
CMRX
|
-82.1 M | - | - | $ 756 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-114 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Corcept Therapeutics Incorporated
CORT
|
141 M | $ 37.35 | -0.4 % | $ 3.86 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
164 M | $ 23.18 | 2.02 % | $ 2.75 B | USA |
 |
AIkido Pharma
AIKI
|
-14.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-58.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-298 M | $ 55.11 | 3.49 % | $ 4.45 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-366 M | $ 55.17 | 2.47 % | $ 4.65 B |  Schweiz |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
Zentalis Pharmaceuticals
ZNTL
|
-292 M | $ 3.53 | -5.75 % | $ 231 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
160 M | $ 29.43 | 6.09 % | $ 1.43 B | USA |